YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
about
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationRole of tumor associated macrophages in tumor angiogenesis and lymphangiogenesisRIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary MetastasisAssociations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 DiabetesSimulating tumor microenvironment: changes in protein expression in an in vitro co-culture system.YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies.Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyYKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer.Serum markers in early-stage and locally advanced melanoma.IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses.YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies.YKL-40/CHI3L1 drives inflammation on the road of tumor progression.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transitionhYKL-40 cancer biomarker electroanalysis in serum samples and model cell lysates: capacitive immunosensing compared with enzyme label immunosorbent assays (ELISA).Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish PatientsSmall cell lung cancer: Recruitment of macrophages by circulating tumor cells.YKL-40 protein in osteosarcoma tumor tissue.Therapeutic application of anti-angiogenic nanomaterials in cancers.Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases.Commentary: IL-4 and IL-13 receptors and signalingThe regulation of angiogenesis by tissue cell-macrophage interactions.YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
P2860
Q26781833-581F02FF-E0C8-4978-B16B-50E428C9BF42Q26865533-907871C8-A8F0-4F97-9866-6DD2C199F048Q28275702-D5845D99-17BA-4EC4-A1D9-F274581C8418Q28546703-8D282D2C-8A76-40DB-98BA-D1844CD378D5Q33687149-6EBBB40C-2064-45E7-85C8-42AD6547ECB5Q33784904-E0D68D33-E02B-4D58-9E02-DE3298736C02Q33785553-15EF8058-D2A1-46DD-BF6B-83D978588256Q35433475-6AF3A110-7044-45AC-B891-158848D0CFF2Q35746711-CF0CA602-1CCB-457E-B69D-827E5FDAAFF3Q36352802-F8BDF6AD-EBE8-45C6-ADF1-72BCDF6462C4Q37264739-D8859E34-F1AB-4E37-8F2F-84B4BB3983EFQ37482262-348A303D-9C6F-4DF1-8FDD-BA01A2D3D2ACQ37537572-FF3EB24D-ACB4-4A79-89A0-5EAA939BAD96Q37733730-95076B0E-BD7F-4721-892D-1A7426C8F9A4Q38393888-908DD115-B02D-48DD-B527-3BB7C277ECF5Q38574540-812E811F-9A11-4582-8FFF-58B55AC15912Q38675589-2F5C963F-8C1B-49DA-A49E-DDFF47DE0546Q38693620-01CFE6DC-E3F3-41E2-AC43-9E1E163B824BQ38720400-3A1F474F-EA20-49B5-AEA1-DCD9F4134D79Q38726476-F168BE04-B4E8-445F-83C9-902E1E616650Q38773484-9DBC3AAD-1277-450C-9E6D-2D26D589AD9EQ38785342-6E4D3018-3E95-48A0-874D-15F448C28449Q38805034-BF2FC0F7-D243-48D9-98D5-19AB694A517BQ38836316-F5C90DD1-545F-47FD-B394-95A24301E58CQ41818218-F123E431-60C3-495F-8715-1A4E6F4DC43DQ42079591-965CD785-A606-4E2D-B505-276E98C8A102Q45811351-A98B00B2-A61B-421A-B57B-7AC2BD2D2C9AQ50293199-2A6EE4B0-AB3E-4978-BB87-9986EE817CC9Q52593486-288018A7-F042-4F37-8B73-0ECE3CFDF95DQ54967714-71539233-E460-4BAA-896A-9A2EB5E9147DQ58767748-98C1707E-7B82-4BEC-B21A-278C8B17864E
P2860
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
@en
type
label
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
@en
prefLabel
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
@en
P2860
P356
P1476
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
@en
P2093
P2860
P356
10.3389/FPHYS.2013.00122
P577
2013-05-28T00:00:00Z